These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

407 related items for PubMed ID: 26628419

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Rationale, design, and baseline characteristics of a trial for the prevention of diabetic atherosclerosis using a DPP-4 inhibitor: the Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A).
    Katakami N, Mita T, Yoshii H, Onuma T, Kaneto H, Osonoi T, Shiraiwa T, Kosugi K, Umayahara Y, Yamamoto T, Yokoyama H, Kuribayashi N, Jinnouchi H, Gosho M, Watada H, Shimomura I, Collaborators on the Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis Trial.
    J Atheroscler Thromb; 2013; 20(12):893-902. PubMed ID: 23965491
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Tofogliflozin does not delay progression of carotid atherosclerosis in patients with type 2 diabetes: a prospective, randomized, open-label, parallel-group comparative study.
    Katakami N, Mita T, Yoshii H, Shiraiwa T, Yasuda T, Okada Y, Torimoto K, Umayahara Y, Kaneto H, Osonoi T, Yamamoto T, Kuribayashi N, Maeda K, Yokoyama H, Kosugi K, Ohtoshi K, Hayashi I, Sumitani S, Tsugawa M, Ryomoto K, Taki H, Nakamura T, Kawashima S, Sato Y, Watada H, Shimomura I, UTOPIA study investigators.
    Cardiovasc Diabetol; 2020 Jul 09; 19(1):110. PubMed ID: 32646498
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Alogliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes mellitus.
    Jarvis CI, Cabrera A, Charron D.
    Ann Pharmacother; 2013 Nov 09; 47(11):1532-9. PubMed ID: 24285765
    [Abstract] [Full Text] [Related]

  • 9. A novel dipeptidyl peptidase-4 inhibitor, alogliptin (SYR-322), is effective in diabetic rats with sulfonylurea-induced secondary failure.
    Asakawa T, Moritoh Y, Kataoka O, Suzuki N, Takeuchi K, Odaka H.
    Life Sci; 2009 Jul 17; 85(3-4):122-6. PubMed ID: 19427871
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The Effect of Sitagliptin on Carotid Artery Atherosclerosis in Type 2 Diabetes: The PROLOGUE Randomized Controlled Trial.
    Oyama J, Murohara T, Kitakaze M, Ishizu T, Sato Y, Kitagawa K, Kamiya H, Ajioka M, Ishihara M, Dai K, Nanasato M, Sata M, Maemura K, Tomiyama H, Higashi Y, Kaku K, Yamada H, Matsuhisa M, Yamashita K, Bando YK, Kashihara N, Ueda S, Inoue T, Tanaka A, Node K, PROLOGUE Study Investigators.
    PLoS Med; 2016 Jun 17; 13(6):e1002051. PubMed ID: 27351380
    [Abstract] [Full Text] [Related]

  • 13. Combining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and beta-cell function in db/db mice.
    Moritoh Y, Takeuchi K, Asakawa T, Kataoka O, Odaka H.
    Br J Pharmacol; 2009 Jun 17; 157(3):415-26. PubMed ID: 19371350
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Alogliptin].
    Tanabe A, Kaku K.
    Nihon Rinsho; 2011 May 17; 69(5):871-6. PubMed ID: 21595274
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The dipeptidyl peptidase-4 inhibitor alogliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis.
    Fujii Y, Abe M, Higuchi T, Mizuno M, Suzuki H, Matsumoto S, Ito M, Maruyama N, Okada K, Soma M.
    Expert Opin Pharmacother; 2013 Feb 17; 14(3):259-67. PubMed ID: 23289982
    [Abstract] [Full Text] [Related]

  • 20. The pharmacokinetics and pharmacodynamics of alogliptin in children, adolescents, and adults with type 2 diabetes mellitus.
    Dudkowski C, Tsai M, Liu J, Zhao Z, Schmidt E, Xie J.
    Eur J Clin Pharmacol; 2017 Mar 17; 73(3):279-288. PubMed ID: 27999883
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.